Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Covalon Receives Patents in France, Germany and UK for Drug Delivery via Therapeutic Hydrogels.


MISSISSAUGA, Ontario -- Covalon Technologies Ltd. ("Covalon") (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension
 VENTURE:COV COV Composés Organiques Volatiles (French)
COV Compuestos Orgánicos Volátiles (Spanish: Volatile Organic Compounds)
COV Coefficient of Variation
COV City of Villians (game) 
) has received notice that patents have issued in France, Germany and the United Kingdom for its technology entitled: "Drug delivery via therapeutic hydrogels".

The technology can be used as a drug delivery platform involving the retention of a drug within liposomes Liposomes

Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end.
 which are microscopic spheres of lipid designed to act as time-release drug depots.

The medical devices that may benefit form the technology include wound dressings, implantable medical devices and wound closure systems useful for helping to reduce hospital acquired infection. The type of therapeutic agent that can be encapsulated within the liposomes is not restricted to a single type of antiseptic or combination of one or more of these. The hydrogel hy·dro·gel
n.
A colloidal gel in which the particles are dispersed in water.



hydrogel

a gel that contains water.

hydrogel Wound care A polymer absorptive wound dressing. See Dressing.
 composition might comprise a variety of active agents and include antibiotics, hormones, growth factors and other factors that are beneficial for the medical condition under management.

The issued patents augment Covalon's technology position in the expanding area of convergent medical devices.

Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility biocompatibility

the quality of not having toxic or injurious effects on biological systems.

biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2.
, and microbial microbial

pertaining to or emanating from a microbe.


microbial digestion
the breakdown of organic material, especially feedstuffs, by microbial organisms.
 attachment.

The TSX Venture Exchange TSX Venture Exchange

Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors.
 has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.

The TSX Venture Exchange has not reviewed and does not accept resp onsibility for the adequacy or accuracy of this release.

Covalon Technologies Ltd. (TSX VENTURE:COV)
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 28, 2006
Words:329
Previous Article:Mentor Graphics Corporation Announces Pricing of Private Placement of 6.25% Convertible Subordinated Debentures Due 2026.
Next Article:CHA Hollywood Presbyterian Medical Center's Korean Care Center Recognized by County of Los Angeles.
Topics:



Related Articles
Hemostatic product.
Beyond Jell-O: new ideas gel in the lab. (This Week).
TOPICAL TRIAL OF MELANOTAN GETS UK REGULATORY APPROVAL.
AVI BIOPHARMA INITIATES PHASE II CARDIOVASCULAR CLINICAL STUDY.
Covalon Receives Health Canada Approval for Its Antimicrobial Coating on Foley Catheters.
Medical polymers conference planned.
Hydromer, Inc. Announces a Hydrogel for Evaluation in Wound Dressings and Drug Delivery Systems.
Theragenex and Pharmaceutical Productions Inc. (PPI) to Collaborate on Novel Transmucosal Drug Delivery Technology.
Global Drug Delivery Includes A Five-Year Forecast Of The Industry.
AerovectRx Granted Notice of Allowance for Key Patent Claims.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles